Literature DB >> 10861259

High prevalence of potentially virulent strains of Helicobacter pylori in the general male British population.

J Danesh1, P Whincup, M Walker, L Lennon, A Thomson, P Appleby, C Hawkey, J C Atherton.   

Abstract

BACKGROUND: Strains of Helicobacter pylori that express the cytotoxin associated gene product A (CagA) may be more strongly associated with serious gastric diseases, such as gastric cancer and peptic ulceration, than other strains. Data, however, are sparse on the prevalence, risk factors, and other correlates of these strains in the general population. AIM: To characterise aspects of the seroepidemiology of CagA(+) strains of H pylori in the general British population.
METHODS: We measured serum IgG antibodies to mixed H pylori antigens and separately to CagA in 1025 men aged 40-59 years who were randomly selected from a larger group of participants in a community based survey conducted in 18 different British towns.
RESULTS: Overall, 44% (95% confidence interval 41-47%) of the men were seropositive to CagA antibodies, representing about 61% (57-65%) of the men seropositive to mixed antigen H pylori. The risk factors for seropositivity to CagA antibodies were similar to those for seropositivity to mixed antigen H pylori, apart from an increased prevalence of reported bedroom sharing in childhood (p<0.01).
CONCLUSION: In a nationwide study of potentially virulent H pylori strains, there was a high prevalence of the infection, with some evidence that acquisition of such strains might occur earlier in life than other strains.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10861259      PMCID: PMC1727943          DOI: 10.1136/gut.47.1.23

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  13 in total

1.  Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection.

Authors:  J Parsonnet; G D Friedman; N Orentreich; H Vogelman
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

2.  Not all Helicobacter pylori strains are created equal: should all be eliminated?

Authors:  M J Blaser
Journal:  Lancet       Date:  1997-04-05       Impact factor: 79.321

Review 3.  H. pylori virulence factors.

Authors:  J C Atherton
Journal:  Br Med Bull       Date:  1998       Impact factor: 4.291

4.  The interrelationship between cytotoxin-associated gene A, vacuolating cytotoxin, and Helicobacter pylori-related diseases.

Authors:  J F Weel; R W van der Hulst; Y Gerrits; P Roorda; M Feller; J Dankert; G N Tytgat; A van der Ende
Journal:  J Infect Dis       Date:  1996-05       Impact factor: 5.226

5.  Density of Helicobacter pylori infection in vivo as assessed by quantitative culture and histology.

Authors:  J C Atherton; K T Tham; R M Peek; T L Cover; M J Blaser
Journal:  J Infect Dis       Date:  1996-09       Impact factor: 5.226

6.  Seroprevalence of CagA-positive strains among Helicobacter pylori-infected, healthy young adults.

Authors:  J Parsonnet; M Replogle; S Yang; R Hiatt
Journal:  J Infect Dis       Date:  1997-05       Impact factor: 5.226

7.  Age at establishment of Helicobacter pylori infection and gastric carcinoma, gastric ulcer, and duodenal ulcer risk.

Authors:  M J Blaser; P H Chyou; A Nomura
Journal:  Cancer Res       Date:  1995-02-01       Impact factor: 12.701

8.  British Regional Heart Study: cardiovascular risk factors in middle-aged men in 24 towns.

Authors:  A G Shaper; S J Pocock; M Walker; N M Cohen; C J Wale; A G Thomson
Journal:  Br Med J (Clin Res Ed)       Date:  1981-07-18

9.  Analysis of genetic diversity in cytotoxin-producing and non-cytotoxin-producing Helicobacter pylori strains.

Authors:  J A Garner; T L Cover
Journal:  J Infect Dis       Date:  1995-07       Impact factor: 5.226

10.  Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach.

Authors:  M J Blaser; G I Perez-Perez; H Kleanthous; T L Cover; R M Peek; P H Chyou; G N Stemmermann; A Nomura
Journal:  Cancer Res       Date:  1995-05-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.